Well, a disappointing day for the stock but IPIX h
Post# of 72440
I was pleased to hear Leo's responses to Cabel's questions. They gave good answers to questions many of us had. I was glad to hear about the placebo being a bit lower than normal. Our 36.8% certainly looks more impressive compared to 70% instead of the 60% our trial showed. Cutting the incidence of severe OM by 50% is an impressive feat but 38.7% will do for now.
I think we will be pleased with the secondary outcomes and a decent deal will be struck. Most importantly this is a big step forward for treatment of OM for a large percentage of cancer patients. We'll toast the IPIX team for advancing yet another drug through mid-stage trials. Thanks to all real investors lending their support as well.
Go IPIX!